Cellectis (CLLS) Current Deferred Revenue (2016 - 2026)

Cellectis' Current Deferred Revenue history runs 11 years deep, the most recent figure standing at $93.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 17.87% year-over-year to $93.1 million; the TTM figure through Mar 2026 stood at $93.1 million (down 17.87% YoY), while the FY2025 annual figure was $96.8 million, down 13.69% from the prior year.
• Current Deferred Revenue was $93.1 million for Q1 2026 at Cellectis, down from $96.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $122.0 million in Q3 2024 to a low of $59000.0 in Q4 2022.
• Historically, Current Deferred Revenue has averaged $64.4 million across 5 years, with a median of $94.0 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue slumped 80.4% in 2022, then surged 186891.53% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $59000.0 in 2022, then soared by 186891.53% to $110.3 million in 2023, then increased by 1.66% to $112.2 million in 2024, then slipped by 13.69% to $96.8 million in 2025, then fell by 3.86% to $93.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $93.1 million (Q1 2026), $96.8 million (Q4 2025), and $94.0 million (Q3 2025), per Business Quant data.